Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
3-hydroxy-3-methylglutaryl-CoA lyase like 1 (HMGCLL1) is a non-mitochondrial enzyme that catalyzes the cation-dependent cleavage of (S)-3-hydroxy-3-methylglutaryl-CoA into acetyl-CoA and acetoacetate, a key reaction in ketogenesis, enabling nonhepatic tissues to produce ketone bodies for energy. It is localized primarily in the cytosol and endoplasmic reticulum, is structurally and functionally related to the mitochondrial HMG-CoA lyase (HMGCL), but is genetically distinct and lacks the N-terminal mitochondrial targeting sequence. HMGCLL1 displays broad tissue expression with predicted enrichment in the brain and is notably detected in certain brain cancer cells such as glioblastoma, where it localizes to Golgi-derived vesicles. While its full physiological and clinical relevance remain incompletely defined, current evidence suggests it plays a supportive metabolic role in extramitochondrial ketone body biosynthesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 3-hydroxy-3-methylglutaryl-CoA lyase like 1 (HMGCLL1).